Needham Maintains Buy on Cartesian Therapeutics, Raises Price Target to $42
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $40 to $42.
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $40 to $42.